Core Viewpoint - Humana Inc. is expected to report a significant decline in earnings per share for Q2 2024, with a consensus estimate of $5.89, down 34.1% from $8.94 in the prior year, while revenues are projected to increase by 11.3% to $28.6 billion [1][14]. Financial Performance Expectations - The Zacks Consensus Estimate indicates a 6.7% increase in premiums compared to the prior year, with a model prediction of 5.2% growth, and Medicare Advantage membership is expected to grow by 5.4% [7]. - Investment income is anticipated to rise nearly 33% from the previous year [7]. - The CenterWell segment is projected to see an 18.2% increase in operating income, with an improvement in the operating cost ratio by 90 basis points to 91.7% [8]. Cost and Margin Challenges - Increased marketing and distribution investments, along with rising benefits, are expected to elevate costs, impacting margins negatively [9]. - Total operating expenses are estimated to rise by 7.1% year-over-year, driven by higher costs associated with resumed elective procedures [10]. - The Insurance segment's pretax income is projected to decline by almost 21% compared to the prior year, despite growth in the CenterWell unit [11]. Stock Performance - Humana's stock has decreased by 14.3% year-to-date, underperforming both the industry, which rose by 6.2%, and the S&P 500 Index, which increased by 14.6% [12]. Conclusion - The decline in membership levels in Stand-Alone PDPs and Specialty Medical, coupled with rising expenses, is likely to hinder Humana's bottom line in the upcoming quarter, making an earnings beat uncertain despite rising premiums and investment income [14].

Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock. The collective assessment of analysts points to an estimated 'Revenues- Investment income (loss)' of $304.69 million. The esti ...

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Humana Inc. ("Humana" or the "Company") (NYSE: HUM) and reminds investors of the August 2, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading st ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Humana To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Humana stock or options between July 27, 2022 and January 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faru ...

Core Insights - Walmart is closing its retail health clinics and telehealth operations, while Humana's CenterWell plans to open senior-focused primary care centers at 23 former Walmart Health locations in Florida, Georgia, Missouri, and Texas [1][2][3] Group 1: Company Actions - Humana's CenterWell will lease clinical space from Walmart to establish primary care centers specifically designed for seniors [2][3] - The new centers will operate under the "CenterWell Senior Primary Care and Conviva Care Centers" brand names, enhancing access to primary care services for older adults [3][4] - Financial terms of the leasing deal were not disclosed, but CenterWell aims to have the centers operational by the first half of 2025 [3] Group 2: Market Context - This development follows Walmart's decision to close its 51 Walmart Health centers and its telehealth business, citing a lack of a sustainable business model in primary care [3] - Humana, as a major provider of privatized Medicare healthcare coverage in the U.S., is well-positioned to integrate these new primary care centers into its health plan networks [4] Group 3: Strategic Goals - CenterWell's president expressed enthusiasm for the partnership with Walmart, emphasizing the goal of providing seniors with greater access to integrated care [5] - The design of the new centers will include dedicated entrances and easy parking, catering specifically to the needs of senior patients [5]

To join the Humana class action, go to https://rosenlegal.com/submit-form/?case_id=25679 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. SO WHAT: If you purchased Humana common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 1 ...

ALLEGATIONS: According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose that: Specifically, defendants downplayed pressures on the Company's adjusted earnings per share resulting from increased medical costs associated with pent-up demand for healthcare procedures which, contrary to the Company's assurances, resulted in increased utilization rates and costs. NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of HUM during ...

Shareholders who purchased shares of HUM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. ALLEGATIONS: According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose that: Specifically, defendants downplayed pressures on the Company's adjusted earnings per share resulting from increased medical costs associated with pent-up ...

NEW YORK, July 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humana Inc. (NYSE: HUM). Shareholders who purchased shares of HUM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. https://securitiesclasslaw.com/securities/humana-loss-submission-form/?id=90355&from=4 ALLEGATIONS: According to the filed complaint, defendants made fal ...

NEW YORK, July 11, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Humana Inc. (NYSE: HUM) between July 27, 2022 and January 24, 2024, both dates inclusive (the "Class Period"), of the important August 2, 2024 lead plaintiff deadline. What to do next: To join the Humana class action, go to https://rosenlegal.com/submit-form/?case_id=25679 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the cl ...